L-Nutra Australia

L-Nutra Australia is the Australian distributor of Prolon, the fasting mimicking diet kit from US company, L-Nutra Inc.

L-Nutra Australia

Michael Thomsen

ABN 44 622 435 116
29 Macfarlane Street
South Hobart Tasmania 7004
Mobile: 0438 700 287
Email reception

L-Nutra Background

L-Nutra Inc. was formed in 2009 by one of the leaders in research on nutrition and aging at the University of Southern California Longevity Institute in the School of Gerontology, one of the oldest and most elite centers for research on aging. Over 18 years of Research and Development with the support of the National Institute for Aging and the National Cancer Institute has gone into building our pipeline.

Based on the identification of the genes and pathways that regulate aging and cellular protection and of the nutrients and conditions that regulate these genes discovered by its founder, L-Nutra has developed and is clinically testing a line of products to delay aging, and promote a healthy lifestyle.

These products activate repair, protection, and regenerative processes that normally remain inactive in the human body. They exploit the ability of fasting to trigger these mechanisms and achieve these effects with sophisticated science based proprietary formulations of ingredients without having to fast. These clinically tested formulations provide nourishment and allow subjects to enjoy a number of great tasting foods that are plant based. These products are called “Fasting Mimicking & Enhancing™ Diets (FMEDs™) since they mimic fasting but allow the consumption of a restricted but relatively normal and highly nutritious diet. Based on decades of research and discoveries made at USC and UCLA, L-Nutra scientists have carefully thought through each component of these foods to trigger different cellular and systemic responses and exploited this knowledge to promote a wide variety of protective and rejuvenating effects.

L-Nutra Inc is incorporated in Australia operating as L-Nutra Australia.

Brian K. Kennedy, PhD

Brian K. Kennedy, PhD

Board member

Buck Institute for Research on Aging

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and is a visionary committed to translating research discoveries into new ways of delaying, detecting, preventing and treating age-related conditions. He leads a team of 20 principal investigators at the Buck Institute – all of whom are involved in interdisciplinary research aimed at extending healthspan, the healthy years of life.

Dr. Kennedy became the Buck Institute’s second CEO in July, 2010, coming from the University of Washington in Seattle where he served in the Department of Biochemistry. He earned his Ph.D. from the Massachusetts Institute of Technology and is well known for work during his graduate studies with Leonard Guarente PhD, which led to the discovery that Sirtuins (SIR2) modulate aging.

Dr. Kennedy’s current work involves nutrient signaling pathways linked to dietary restriction, particularly the TOR pathway, which generated excitement in the age research field when it was shown recently that the drug Rapamycin can extend mouse lifespan. One of the goals of his research is to determine whether pathways like TOR can be regulated to treat the diseases of aging. Specifically, Dr. Kennedy’s lab focuses on cardiovascular disease and metabolic syndromes like type II diabetes. Dr. Kennedy also studies the genetic mutations underlying diseases such as dilated cardiomyopathy, muscular dystrophy and Hutchinson-Gilford Progeria Syndrome, which resembles premature aging.

Dr. Kennedy is the inventor on several patents and co-founder of two U.S. companies aimed at developing treatments for age-related chronic disease. He is actively involved in aging research in the Pacific Rim, which features the largest elderly population in the world. He is a visiting professor at the Aging Research Institute at Guangdong Medical College in China. In the past year he lectured in Korea, Russia, China, Chile, Germany, Norway, Singapore and the United Kingdom. In conjunction with the University of Southern California, he also launched the nation’s first PhD Program in the Biology of Aging.

Dr. Kennedy has published more than 150 manuscripts in prestigious journals including Science and Nature and has been quoted in The Wall Street Journal, The New York Times and The Boston Globe, among more than 20 other publications. He serves as a public advocate for interventional strategies to promote health aging, including in a recent nationally broadcasted radio debate available online at the Intelligence Squared Foundation website. He is also co-Editor-in-Chief of Aging Cell, Board Chairman of Mt. Tam Biotechnologies, and serves as a consultant for other biotech, pharmaceutical, and health-related companies.